Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Total Enrollment
2200 participants
Study Classification
OBSERVATIONAL
Study Start Date
2020-10-12
Study Completion Date
2032-10-12
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The identification of myocardial fibrosis in term of myocardial scar and extracellular matrix remodelling assessed respectively with the technique of Late Gadolinium Enhancement (LGE) and with the quantification of the Extracellular Volume Fraction (ECV) in Cardiac Magnetic Resonance has been demonstrated to be crucial in the diagnosis of different cardiomyopathy and to be prognosticators of major cardiovascular adverse events \[1-14\].
For these reason CMR represent the gold standard for the non-invasive characterization of myocardial tissue in the clinical practice.
However, regardless of its indisputable clinical role, CMR has many limitations: 1) it does not allow to evaluate coronary arteries; 2) it is contraindicated in patients with cardiac devices, and in case of conditional device they may also significantly impair LGE assessability due to artefacts \[19\]); 2) has limited availability and it is time consuming, therefore it is difficult to perform in the acute setting also because of poor patient compliance; 3) it is not feasible in patients suffering from claustrophobia. Cardiac Computed Tomography (cCT) is the image of choice to non-invasively study coronary arteries, not assessable with CMR. Moreover the recent technological advancement has continuously increased the clinical indication to the evaluation of cardiac valve and fibrosis, with reduced acquisition time respect to CMR (few minutes vs 1 hour), radiation exposure and costs.
cCT has emerging as a possible alternative to CMR in the characterization of myocardial scar and extracellular volume fraction, with the advantage of a single shot evaluation of coronary arteries and myocardial tissue remodelling (scar, diffuse fibrosis, contractility..).In particular, several studies including some from our group, have demonstrated the clinical utility of myocardial tissue characterization with cCT in different clinical settings, such as myocardial infarction \[20, 21\], myocarditis \[22\], hypertrophic cardiomyopathy (HCM) \[23\], heart failure \[24\], ventricular tachycardia \[25\], and sarcoidosis \[26\]. Despite the interesting results, all these previous studies are limited on highly selected and small sample size. Moreover, any large study with long term follow-up is available in the setting of tissue characterization (myocardial scar and ECV) in cCT also as well as combined with a multiparametric approach (cardiac chamber morphofuntionality,contractility-strain, valve calcification, geometry, coronary atherosclerosis, myocardial perfusion, myocardial strain and texture) and no data are available about its prognostic impact. Aim of the study is to evaluate the potential of cCT in tissue characterization (myocardial scar and ECV) alone and associate to other CT imaging biomarker on a large population of patient clinically candidate to cardiac CT.
For these reason CMR represent the gold standard for the non-invasive characterization of myocardial tissue in the clinical practice.
However, regardless of its indisputable clinical role, CMR has many limitations: 1) it does not allow to evaluate coronary arteries; 2) it is contraindicated in patients with cardiac devices, and in case of conditional device they may also significantly impair LGE assessability due to artefacts \[19\]); 2) has limited availability and it is time consuming, therefore it is difficult to perform in the acute setting also because of poor patient compliance; 3) it is not feasible in patients suffering from claustrophobia. Cardiac Computed Tomography (cCT) is the image of choice to non-invasively study coronary arteries, not assessable with CMR. Moreover the recent technological advancement has continuously increased the clinical indication to the evaluation of cardiac valve and fibrosis, with reduced acquisition time respect to CMR (few minutes vs 1 hour), radiation exposure and costs.
cCT has emerging as a possible alternative to CMR in the characterization of myocardial scar and extracellular volume fraction, with the advantage of a single shot evaluation of coronary arteries and myocardial tissue remodelling (scar, diffuse fibrosis, contractility..).In particular, several studies including some from our group, have demonstrated the clinical utility of myocardial tissue characterization with cCT in different clinical settings, such as myocardial infarction \[20, 21\], myocarditis \[22\], hypertrophic cardiomyopathy (HCM) \[23\], heart failure \[24\], ventricular tachycardia \[25\], and sarcoidosis \[26\]. Despite the interesting results, all these previous studies are limited on highly selected and small sample size. Moreover, any large study with long term follow-up is available in the setting of tissue characterization (myocardial scar and ECV) in cCT also as well as combined with a multiparametric approach (cardiac chamber morphofuntionality,contractility-strain, valve calcification, geometry, coronary atherosclerosis, myocardial perfusion, myocardial strain and texture) and no data are available about its prognostic impact. Aim of the study is to evaluate the potential of cCT in tissue characterization (myocardial scar and ECV) alone and associate to other CT imaging biomarker on a large population of patient clinically candidate to cardiac CT.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prognostic Value of Myocardial Fibrosis Quantified Using CMR in Patient With Dilated Cardiomyopathy
NCT02352129
Cardiomyopathy, Dilated
COMPLETED
NA
Prognotic Role of CMR in Takotsubo Syndrome
NCT06277297
Takotsubo Cardiomyopathy
Machine Learning
Magnetic Resonance Imaging
RECRUITING
International T1 Multicentre CMR Outcome Study
NCT02407197
Cardiomyopathy
Heart Failure
Coronary Artery Disease
+3 more
COMPLETED
International T1 Multicenter Outcome Study
NCT03749343
Heart Failure
Cardiomyopathies
Inflammatory Disease
+2 more
ACTIVE_NOT_RECRUITING
IMPRoving Cardiovascular RiSk Stratification Using T1 Mapping in General populatION
NCT04444128
Myocarditis
Heart Failure
Myocardial Fibrosis
+2 more
RECRUITING
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Cardiovascular Diseases
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
COHORT
Study Time Perspective
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Retrospective cohort
The retrospective arm of the study will include 200 patients meeting the inclusion criteria who have received a cardiac CT from January 2013 to date of approval amendment. (2013 was chosen as starting year to retrieve CT and clinical date in order to have at least 5 years of follow-up per patients).
No interventions assigned to this group
Prospective cohort
The prospective arm of the study will include 2000 consecutive patients meeting the inclusion criteria, candidate to cardiac CT along the 7 years after date of approval.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* age ≥ 18 years;
* no contraindication to cCT
* signed informed consent
* clinical indication to cCT for the following reason: stable angina, heart failure, atrial/ ventricular arrhythmias, acute chest pain with need of "triple-rule-out" scan, planning of valvular repair/substitution, structural and infiltrative cardiomyopathy, new onset ECG alteration, troponin increase.
* no contraindication to cCT
* signed informed consent
* clinical indication to cCT for the following reason: stable angina, heart failure, atrial/ ventricular arrhythmias, acute chest pain with need of "triple-rule-out" scan, planning of valvular repair/substitution, structural and infiltrative cardiomyopathy, new onset ECG alteration, troponin increase.
Exclusion Criteria
* age \< 18 years
* pregnancy and/or breastfeeding
* contraindications to iodinated contrast agent administration or impaired renal function (eGFR ≤ 30 mL/min);
* inability to sustain a brief breath hold (5 seconds)
* pregnancy and/or breastfeeding
* contraindications to iodinated contrast agent administration or impaired renal function (eGFR ≤ 30 mL/min);
* inability to sustain a brief breath hold (5 seconds)
Minimum Eligible Age
18 Years
Maximum Eligible Age
100 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
IRCCS San Raffaele
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Antonio Esposito
Professor
Responsibility Role
PRINCIPAL_INVESTIGATOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
IRCCS San Raffaele
Milan, , Italy
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Italy
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Mewton N, Liu CY, Croisille P, Bluemke D, Lima JA. Assessment of myocardial fibrosis with cardiovascular magnetic resonance. J Am Coll Cardiol. 2011 Feb 22;57(8):891-903. doi: 10.1016/j.jacc.2010.11.013.
Reference Type
BACKGROUND
Kuruvilla S, Adenaw N, Katwal AB, Lipinski MJ, Kramer CM, Salerno M. Late gadolinium enhancement on cardiac magnetic resonance predicts adverse cardiovascular outcomes in nonischemic cardiomyopathy: a systematic review and meta-analysis. Circ Cardiovasc Imaging. 2014 Mar;7(2):250-258. doi: 10.1161/CIRCIMAGING.113.001144. Epub 2013 Dec 20.
Reference Type
BACKGROUND
Mavrogeni S, Petrou E, Kolovou G, Theodorakis G, Iliodromitis E. Prediction of ventricular arrhythmias using cardiovascular magnetic resonance. Eur Heart J Cardiovasc Imaging. 2013 Jun;14(6):518-25. doi: 10.1093/ehjci/jes302. Epub 2013 Jan 16.
Reference Type
BACKGROUND
Weng Z, Yao J, Chan RH, He J, Yang X, Zhou Y, He Y. Prognostic Value of LGE-CMR in HCM: A Meta-Analysis. JACC Cardiovasc Imaging. 2016 Dec;9(12):1392-1402. doi: 10.1016/j.jcmg.2016.02.031. Epub 2016 Jul 20.
Reference Type
BACKGROUND
Haaf P, Garg P, Messroghli DR, Broadbent DA, Greenwood JP, Plein S. Cardiac T1 Mapping and Extracellular Volume (ECV) in clinical practice: a comprehensive review. J Cardiovasc Magn Reson. 2016 Nov 30;18(1):89. doi: 10.1186/s12968-016-0308-4.
Reference Type
BACKGROUND
Bulluck H, Hammond-Haley M, Fontana M, Knight DS, Sirker A, Herrey AS, Manisty C, Kellman P, Moon JC, Hausenloy DJ. Quantification of both the area-at-risk and acute myocardial infarct size in ST-segment elevation myocardial infarction using T1-mapping. J Cardiovasc Magn Reson. 2017 Aug 1;19(1):57. doi: 10.1186/s12968-017-0370-6.
Reference Type
BACKGROUND
Youn JC, Hong YJ, Lee HJ, Han K, Shim CY, Hong GR, Suh YJ, Hur J, Kim YJ, Choi BW, Kang SM. Contrast-enhanced T1 mapping-based extracellular volume fraction independently predicts clinical outcome in patients with non-ischemic dilated cardiomyopathy: a prospective cohort study. Eur Radiol. 2017 Sep;27(9):3924-3933. doi: 10.1007/s00330-017-4817-9. Epub 2017 Apr 24.
Reference Type
BACKGROUND
Ferreira VM, Piechnik SK, Dall'Armellina E, Karamitsos TD, Francis JM, Ntusi N, Holloway C, Choudhury RP, Kardos A, Robson MD, Friedrich MG, Neubauer S. T(1) mapping for the diagnosis of acute myocarditis using CMR: comparison to T2-weighted and late gadolinium enhanced imaging. JACC Cardiovasc Imaging. 2013 Oct;6(10):1048-1058. doi: 10.1016/j.jcmg.2013.03.008. Epub 2013 Sep 4.
Reference Type
BACKGROUND
Knuuti J, Bengel F, Bax JJ, Kaufmann PA, Le Guludec D, Perrone Filardi P, Marcassa C, Ajmone Marsan N, Achenbach S, Kitsiou A, Flotats A, Eeckhout E, Minn H, Hesse B. Risks and benefits of cardiac imaging: an analysis of risks related to imaging for coronary artery disease. Eur Heart J. 2014 Mar;35(10):633-8. doi: 10.1093/eurheartj/eht512. Epub 2013 Dec 29. No abstract available.
Reference Type
BACKGROUND
Hinojar R, Varma N, Child N, Goodman B, Jabbour A, Yu CY, Gebker R, Doltra A, Kelle S, Khan S, Rogers T, Arroyo Ucar E, Cummins C, Carr-White G, Nagel E, Puntmann VO. T1 Mapping in Discrimination of Hypertrophic Phenotypes: Hypertensive Heart Disease and Hypertrophic Cardiomyopathy: Findings From the International T1 Multicenter Cardiovascular Magnetic Resonance Study. Circ Cardiovasc Imaging. 2015 Dec;8(12):e003285. doi: 10.1161/CIRCIMAGING.115.003285.
Reference Type
BACKGROUND
Puntmann VO, Isted A, Hinojar R, Foote L, Carr-White G, Nagel E. T1 and T2 Mapping in Recognition of Early Cardiac Involvement in Systemic Sarcoidosis. Radiology. 2017 Oct;285(1):63-72. doi: 10.1148/radiol.2017162732. Epub 2017 Apr 27.
Reference Type
BACKGROUND
Martinez-Naharro A, Kotecha T, Norrington K, Boldrini M, Rezk T, Quarta C, Treibel TA, Whelan CJ, Knight DS, Kellman P, Ruberg FL, Gillmore JD, Moon JC, Hawkins PN, Fontana M. Native T1 and Extracellular Volume in Transthyretin Amyloidosis. JACC Cardiovasc Imaging. 2019 May;12(5):810-819. doi: 10.1016/j.jcmg.2018.02.006. Epub 2018 Mar 14.
Reference Type
BACKGROUND
Karur GR, Robison S, Iwanochko RM, Morel CF, Crean AM, Thavendiranathan P, Nguyen ET, Mathur S, Wasim S, Hanneman K. Use of Myocardial T1 Mapping at 3.0 T to Differentiate Anderson-Fabry Disease from Hypertrophic Cardiomyopathy. Radiology. 2018 Aug;288(2):398-406. doi: 10.1148/radiol.2018172613. Epub 2018 Apr 24.
Reference Type
BACKGROUND
Neilan TG, Coelho-Filho OR, Shah RV, Feng JH, Pena-Herrera D, Mandry D, Pierre-Mongeon F, Heydari B, Francis SA, Moslehi J, Kwong RY, Jerosch-Herold M. Myocardial extracellular volume by cardiac magnetic resonance imaging in patients treated with anthracycline-based chemotherapy. Am J Cardiol. 2013 Mar 1;111(5):717-22. doi: 10.1016/j.amjcard.2012.11.022. Epub 2012 Dec 8.
Reference Type
BACKGROUND
Treibel TA, Fridman Y, Bering P, Sayeed A, Maanja M, Frojdh F, Niklasson L, Olausson E, Wong TC, Kellman P, Miller CA, Moon JC, Ugander M, Schelbert EB. Extracellular Volume Associates With Outcomes More Strongly Than Native or Post-Contrast Myocardial T1. JACC Cardiovasc Imaging. 2020 Jan;13(1 Pt 1):44-54. doi: 10.1016/j.jcmg.2019.03.017. Epub 2019 May 15.
Reference Type
BACKGROUND
Barone-Rochette G, Pierard S, De Meester de Ravenstein C, Seldrum S, Melchior J, Maes F, Pouleur AC, Vancraeynest D, Pasquet A, Vanoverschelde JL, Gerber BL. Prognostic significance of LGE by CMR in aortic stenosis patients undergoing valve replacement. J Am Coll Cardiol. 2014 Jul 15;64(2):144-54. doi: 10.1016/j.jacc.2014.02.612.
Reference Type
BACKGROUND
Chin CWL, Everett RJ, Kwiecinski J, Vesey AT, Yeung E, Esson G, Jenkins W, Koo M, Mirsadraee S, White AC, Japp AG, Prasad SK, Semple S, Newby DE, Dweck MR. Myocardial Fibrosis and Cardiac Decompensation in Aortic Stenosis. JACC Cardiovasc Imaging. 2017 Nov;10(11):1320-1333. doi: 10.1016/j.jcmg.2016.10.007. Epub 2016 Dec 21.
Reference Type
BACKGROUND
Chaikriangkrai K, Lopez-Mattei JC, Lawrie G, Ibrahim H, Quinones MA, Zoghbi W, Little SH, Shah DJ. Prognostic value of delayed enhancement cardiac magnetic resonance imaging in mitral valve repair. Ann Thorac Surg. 2014 Nov;98(5):1557-63. doi: 10.1016/j.athoracsur.2014.06.049. Epub 2014 Sep 18.
Reference Type
BACKGROUND
Steen H, Madadi-Schroeder M, Lehrke S, Lossnitzer D, Giannitsis E, Katus HA. Staged cardiovascular magnetic resonance for differential diagnosis of troponin T positive patients with low likelihood for acute coronary syndrome. J Cardiovasc Magn Reson. 2010 Sep 14;12(1):51. doi: 10.1186/1532-429X-12-51.
Reference Type
BACKGROUND
Dickfeld T, Tian J, Ahmad G, Jimenez A, Turgeman A, Kuk R, Peters M, Saliaris A, Saba M, Shorofsky S, Jeudy J. MRI-Guided ventricular tachycardia ablation: integration of late gadolinium-enhanced 3D scar in patients with implantable cardioverter-defibrillators. Circ Arrhythm Electrophysiol. 2011 Apr;4(2):172-84. doi: 10.1161/CIRCEP.110.958744. Epub 2011 Jan 26.
Reference Type
BACKGROUND
Tanabe Y, Kido T, Kurata A, Kouchi T, Fukuyama N, Yokoi T, Uetani T, Yamashita N, Miyagawa M, Mochizuki T. Late iodine enhancement computed tomography with image subtraction for assessment of myocardial infarction. Eur Radiol. 2018 Mar;28(3):1285-1292. doi: 10.1007/s00330-017-5048-9. Epub 2017 Sep 19.
Reference Type
BACKGROUND
Rodriguez-Granillo GA. Delayed enhancement cardiac computed tomography for the assessment of myocardial infarction: from bench to bedside. Cardiovasc Diagn Ther. 2017 Apr;7(2):159-170. doi: 10.21037/cdt.2017.03.16.
Reference Type
BACKGROUND
Bouleti C, Baudry G, Iung B, Arangalage D, Abtan J, Ducrocq G, Steg PG, Vahanian A, Henry-Feugeas MC, Pasi N, Chillon S, Pitocco F, Laissy JP, Ou P. Usefulness of Late Iodine Enhancement on Spectral CT in Acute Myocarditis. JACC Cardiovasc Imaging. 2017 Jul;10(7):826-827. doi: 10.1016/j.jcmg.2016.09.013. Epub 2016 Dec 21. No abstract available.
Reference Type
BACKGROUND
Zhao L, Ma X, Delano MC, Jiang T, Zhang C, Liu Y, Zhang Z. Assessment of myocardial fibrosis and coronary arteries in hypertrophic cardiomyopathy using combined arterial and delayed enhanced CT: comparison with MR and coronary angiography. Eur Radiol. 2013 Apr;23(4):1034-43. doi: 10.1007/s00330-012-2674-0. Epub 2012 Oct 14.
Reference Type
BACKGROUND
Ohta Y, Kitao S, Yunaga H, Fujii S, Mukai N, Yamamoto K, Ogawa T. Myocardial Delayed Enhancement CT for the Evaluation of Heart Failure: Comparison to MRI. Radiology. 2018 Sep;288(3):682-691. doi: 10.1148/radiol.2018172523. Epub 2018 Jul 10.
Reference Type
BACKGROUND
Esposito A, Palmisano A, Antunes S, Maccabelli G, Colantoni C, Rancoita PMV, Baratto F, Di Serio C, Rizzo G, De Cobelli F, Della Bella P, Del Maschio A. Cardiac CT With Delayed Enhancement in the Characterization of Ventricular Tachycardia Structural Substrate: Relationship Between CT-Segmented Scar and Electro-Anatomic Mapping. JACC Cardiovasc Imaging. 2016 Jul;9(7):822-832. doi: 10.1016/j.jcmg.2015.10.024. Epub 2016 Feb 17.
Reference Type
BACKGROUND
Aikawa T, Oyama-Manabe N, Naya M, Ohira H, Sugimoto A, Tsujino I, Obara M, Manabe O, Kudo K, Tsutsui H, Tamaki N. Delayed contrast-enhanced computed tomography in patients with known or suspected cardiac sarcoidosis: A feasibility study. Eur Radiol. 2017 Oct;27(10):4054-4063. doi: 10.1007/s00330-017-4824-x. Epub 2017 Apr 5.
Reference Type
BACKGROUND
Nacif MS, Kawel N, Lee JJ, Chen X, Yao J, Zavodni A, Sibley CT, Lima JA, Liu S, Bluemke DA. Interstitial myocardial fibrosis assessed as extracellular volume fraction with low-radiation-dose cardiac CT. Radiology. 2012 Sep;264(3):876-83. doi: 10.1148/radiol.12112458. Epub 2012 Jul 6.
Reference Type
BACKGROUND
Marwan M, Achenbach S, Korosoglou G, Schmermund A, Schneider S, Bruder O, Hausleiter J, Schroeder S, Barth S, Kerber S, Leber A, Moshage W, Senges J. German cardiac CT registry: indications, procedural data and clinical consequences in 7061 patients undergoing cardiac computed tomography. Int J Cardiovasc Imaging. 2018 May;34(5):807-819. doi: 10.1007/s10554-017-1282-0. Epub 2017 Dec 1.
Reference Type
BACKGROUND
Esposito A, Palmisano A, Barbera M, Vignale D, Benedetti G, Spoladore R, Ancona MB, Giannini F, Oppizzi M, Del Maschio A, De Cobelli F. Cardiac Computed Tomography in Troponin-Positive Chest Pain: Sometimes the Answer Lies in the Late Iodine Enhancement or Extracellular Volume Fraction Map. JACC Cardiovasc Imaging. 2019 Apr;12(4):745-748. doi: 10.1016/j.jcmg.2018.08.013. Epub 2018 Oct 17. No abstract available.
Reference Type
BACKGROUND
Vignale D, Palmisano A, Gnasso C, Margonato D, Romagnolo D, Barbieri S, Ingallina G, Stella S, Ancona MB, Montorfano M, Maisano F, Agricola E, Esposito A. Extracellular volume fraction (ECV) derived from pre-operative computed tomography predicts prognosis in patients undergoing transcatheter aortic valve implantation (TAVI). Eur Heart J Cardiovasc Imaging. 2023 Jun 21;24(7):887-896. doi: 10.1093/ehjci/jead040.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CTMyoC
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Magnetocardiography as a Diagnostic Screening Tool for Myocarditis and Other Types of Cardiomyopathy
NCT06689098
COMPLETED
Quantitative Cardiac Parametric Mapping
NCT02855554
RECRUITING
NA
Risk Evaluation by COronary Imaging and Artificial intelliGence Based fuNctIonal analyZing tEchniques - III
NCT06793774
RECRUITING
Consistency of LGE-MRI Fibrosis and EAM Low-voltage Area
NCT06552845
RECRUITING
One-stop Evaluation of Hypertrophic Cardiomyopathy in Cardiac Magnetic Resonance
NCT07336290
ENROLLING_BY_INVITATION
CMR Assessment of Cardiac Microvascular Dysfunction in Patients With HFpEF
NCT06316661
RECRUITING
Cardiac Magnetic Resonance for Diagnosis, Treatment Guidance and Prognosis of Cardiac Masses (CMR)
NCT07335770
ENROLLING_BY_INVITATION
Myocardial Fibrosis, Function and Aging
NCT03064503
UNKNOWN
NA
CMR for Prognosis Assessment in NSTEMI
NCT03516578
COMPLETED
Improved Detection of Myocardial Fibrosis: a Cardiovascular Magnetic Resonance Imaging Study
NCT06697509
ENROLLING_BY_INVITATION
Precision Diagnosis and Risk Stratification of Rare Cardiomyopathies Based on Novel Cardiac Magnetic Resonance Techniques
NCT07336394
RECRUITING
Cardiac Magnetic Resonance - PROgnostic HEart Scar for Sudden Cardiac Death Prediction StudY
NCT07137936
RECRUITING
Safety and Efficacy of MCG for Diagnosing Coronary Heart Disease
NCT00170027
COMPLETED
PHASE3
Cardiomyopathies and Heart Muscle Diseases: Cardiac Imaging in the Evaluation of Myocardial Fibrosis Transition
NCT06409585
RECRUITING
MCG is Clinically Applied to Evaluate Myocardial Ischemic Function in Patients With Stable Coronary Artery Disease
NCT06123728
RECRUITING
Characterization of Irreversible Myocardial Injury in Cardiomyopathies by Contrast-enhanced CMR
NCT00549861
COMPLETED
NA
Myocardial Salvage Assessed by Cardiovascular Magnetic Resonance - Impact on Outcome
NCT00952224
COMPLETED
Evaluation of Cirrhotic Cardiomyopathy by Cardiac MRI in Patients Waiting for Liver Transplant.
NCT06327308
NOT_YET_RECRUITING
Cardiac Magnetic Resonance Assessment for Heart Failure With Preserved Ejection Fraction
NCT04063579
COMPLETED
NA
Reproducibility of Magnetic Resonance Myocardial Salvage Index
NCT00794300
COMPLETED
Imaging-based Diagnosis of Diffuse Coronary Artery Disease and Quantification of Cardiac Remodeling in Obesity
NCT03046823
COMPLETED
Cardiac (CMRI) Assessment of Acromegaly
NCT02948322
COMPLETED
NA
Precision of the Magnetocardiographer for Data Aquision and Analysis.
NCT00170014
COMPLETED
PHASE3
Cardiac Magnetic Resonance Utilities in the Evaluation of Ischemic Heart Disease
NCT01397357
COMPLETED
AI-enabled Screening and Diagnosis of Cardiomyopathies Using Coronary CTA
NCT06748261
NOT_YET_RECRUITING